25.27 USD
-0.63 (-2.43%)
25.27 USD
0 (0%)
Taking everything into account, AMPH scores 6 out of 10 in our fundamental rating. AMPH was compared to 191 industry peers in the Pharmaceuticals industry. While AMPH has a great profitability rating, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on AMPH. These ratings could make AMPH a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year AMPH was profitable.
AMPH had a positive operating cash flow in the past year.
Each year in the past 5 years AMPH has been profitable.
In the past 5 years AMPH always reported a positive cash flow from operatings.
1.2 Ratios
AMPH's Return On Assets of 6.70% is amongst the best of the industry. AMPH outperforms 87.96% of its industry peers.
Looking at the Return On Equity, with a value of 14.37%, AMPH belongs to the top of the industry, outperforming 88.48% of the companies in the same industry.
AMPH has a Return On Invested Capital of 8.51%. This is amongst the best in the industry. AMPH outperforms 86.91% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for AMPH is in line with the industry average of 12.85%.
The 3 year average ROIC (12.92%) for AMPH is well above the current ROIC(8.51%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROIC | 8.51% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
1.3 Margins
AMPH has a better Profit Margin (15.43%) than 87.43% of its industry peers.
AMPH's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 20.73%, AMPH belongs to the best of the industry, outperforming 87.96% of the companies in the same industry.
AMPH's Operating Margin has improved in the last couple of years.
AMPH has a better Gross Margin (49.36%) than 64.40% of its industry peers.
In the last couple of years the Gross Margin of AMPH has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% |
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMPH is creating some value.
The number of shares outstanding for AMPH has been reduced compared to 1 year ago.
The number of shares outstanding for AMPH has been increased compared to 5 years ago.
The debt/assets ratio for AMPH has been reduced compared to a year ago.
2.2 Solvency
AMPH has an Altman-Z score of 2.39. This is not the best score and indicates that AMPH is in the grey zone with still only limited risk for bankruptcy at the moment.
AMPH's Altman-Z score of 2.39 is fine compared to the rest of the industry. AMPH outperforms 62.30% of its industry peers.
The Debt to FCF ratio of AMPH is 5.49, which is a neutral value as it means it would take AMPH, 5.49 years of fcf income to pay off all of its debts.
AMPH has a better Debt to FCF ratio (5.49) than 81.68% of its industry peers.
A Debt/Equity ratio of 0.78 indicates that AMPH is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.78, AMPH is doing worse than 70.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Altman-Z | 2.39 |
ROIC/WACC0.97
WACC8.79%
2.3 Liquidity
AMPH has a Current Ratio of 3.12. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
AMPH has a Current ratio (3.12) which is comparable to the rest of the industry.
AMPH has a Quick Ratio of 2.21. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
AMPH has a Quick ratio (2.21) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
The earnings per share for AMPH have decreased by -9.95% in the last year.
AMPH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 61.62% yearly.
Looking at the last year, AMPH shows a decrease in Revenue. The Revenue has decreased by -0.03% in the last year.
The Revenue has been growing by 17.82% on average over the past years. This is quite good.
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
3.2 Future
The Earnings Per Share is expected to grow by 0.14% on average over the next years.
The Revenue is expected to grow by 4.14% on average over the next years.
EPS Next Y-8.67%
EPS Next 2Y-1.31%
EPS Next 3Y1.28%
EPS Next 5Y0.14%
Revenue Next Year-0.81%
Revenue Next 2Y2.1%
Revenue Next 3Y2.62%
Revenue Next 5Y4.14%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 7.35, which indicates a rather cheap valuation of AMPH.
93.72% of the companies in the same industry are more expensive than AMPH, based on the Price/Earnings ratio.
AMPH is valuated cheaply when we compare the Price/Earnings ratio to 26.54, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 6.72, the valuation of AMPH can be described as very cheap.
Based on the Price/Forward Earnings ratio, AMPH is valued cheaper than 92.67% of the companies in the same industry.
AMPH is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.78, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.35 | ||
| Fwd PE | 6.72 |
4.2 Price Multiples
92.15% of the companies in the same industry are more expensive than AMPH, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, AMPH is valued cheaper than 90.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.46 | ||
| EV/EBITDA | 7.22 |
4.3 Compensation for Growth
AMPH has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.12
EPS Next 2Y-1.31%
EPS Next 3Y1.28%
5. Dividend
5.1 Amount
AMPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
25.27
-0.63 (-2.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners73.83%
Inst Owner Change0.4%
Ins Owners9.39%
Ins Owner Change3.23%
Market Cap1.16B
Revenue(TTM)723.30M
Net Income(TTM)111.63M
Analysts80
Price Target32.64 (29.17%)
Short Float %10.32%
Short Ratio8.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.52%
Min EPS beat(2)10.58%
Max EPS beat(2)12.46%
EPS beat(4)3
Avg EPS beat(4)6.04%
Min EPS beat(4)-4.55%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)4.79%
EPS beat(12)9
Avg EPS beat(12)18.2%
EPS beat(16)12
Avg EPS beat(16)16.54%
Revenue beat(2)1
Avg Revenue beat(2)0.23%
Min Revenue beat(2)-1.36%
Max Revenue beat(2)1.82%
Revenue beat(4)1
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-2.87%
Max Revenue beat(4)1.82%
Revenue beat(8)2
Avg Revenue beat(8)-0.96%
Revenue beat(12)6
Avg Revenue beat(12)0.35%
Revenue beat(16)9
Avg Revenue beat(16)0.62%
PT rev (1m)-3.03%
PT rev (3m)-3.61%
EPS NQ rev (1m)5.33%
EPS NQ rev (3m)1.52%
EPS NY rev (1m)3.69%
EPS NY rev (3m)3.34%
Revenue NQ rev (1m)0.16%
Revenue NQ rev (3m)-2.51%
Revenue NY rev (1m)0.61%
Revenue NY rev (3m)0.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.35 | ||
| Fwd PE | 6.72 | ||
| P/S | 1.61 | ||
| P/FCF | 10.46 | ||
| P/OCF | 7.63 | ||
| P/B | 1.49 | ||
| P/tB | 5.68 | ||
| EV/EBITDA | 7.22 |
EPS(TTM)3.44
EY13.61%
EPS(NY)3.76
Fwd EY14.88%
FCF(TTM)2.42
FCFY9.56%
OCF(TTM)3.31
OCFY13.11%
SpS15.74
BVpS16.9
TBVpS4.45
PEG (NY)N/A
PEG (5Y)0.12
Graham Number36.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROCE | 10.26% | ||
| ROIC | 8.51% | ||
| ROICexc | 10.49% | ||
| ROICexgc | 20.29% | ||
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% | ||
| FCFM | 15.35% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexgc growth 3Y24.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score5
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Debt/EBITDA | 3 | ||
| Cap/Depr | 78.19% | ||
| Cap/Sales | 5.71% | ||
| Interest Coverage | 6.36 | ||
| Cash Conversion | 75.12% | ||
| Profit Quality | 99.44% | ||
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | 2.39 |
F-Score5
WACC8.79%
ROIC/WACC0.97
Cap/Depr(3y)91.01%
Cap/Depr(5y)109.44%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
EPS Next Y-8.67%
EPS Next 2Y-1.31%
EPS Next 3Y1.28%
EPS Next 5Y0.14%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
Revenue Next Year-0.81%
Revenue Next 2Y2.1%
Revenue Next 3Y2.62%
Revenue Next 5Y4.14%
EBIT growth 1Y-30.02%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year1.38%
EBIT Next 3Y0.74%
EBIT Next 5Y5.95%
FCF growth 1Y-20.6%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y-12.89%
OCF growth 3Y29.62%
OCF growth 5Y38.57%
AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ
What is the fundamental rating for AMPH stock?
ChartMill assigns a fundamental rating of 6 / 10 to AMPH.
Can you provide the valuation status for AMPHASTAR PHARMACEUTICALS IN?
ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.
Can you provide the profitability details for AMPHASTAR PHARMACEUTICALS IN?
AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 9 / 10.
How financially healthy is AMPHASTAR PHARMACEUTICALS IN?
The financial health rating of AMPHASTAR PHARMACEUTICALS IN (AMPH) is 6 / 10.
What is the expected EPS growth for AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?
The Earnings per Share (EPS) of AMPHASTAR PHARMACEUTICALS IN (AMPH) is expected to decline by -8.67% in the next year.